Johnson & Johnson to Acquire Abiomed
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St hits two-week lows as rising bond yields, Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Johnson & Johnson's (JNJ) $16.6bn Deal for Abiomed (ABMD) Deal a Positive - Stifel
November 1, 2022 10:00 AM EDTJohnson & Johnson (NYSE: JNJ) announced Tuesday that it has agreed a $16.6 billion deal to acquire heart pump maker Abiomed (NASDAQ: ABMD).
The company will pay $380 per share in cash for Abiomed, representing an over 50% premium to Abiomed's last closing price. The deal is set to be completed before the end of the first quarter of 2023. In addition, Abiomed shareholders will also receive up to $35 per share in cash if certain commercial and clinical milestones are achieved.
Johnson &... More
